Vistagen initiates palisade-4 phase 3 study of fasedienol for the acute treatment of social anxiety disorder

South san francisco, calif.--(business wire)---- $vtgn #mentalhealth--vistagen (nasdaq: vtgn) a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on nose-to-brain neurocircuitry, today announced enrollment of the first subject in its palisade-4 phase 3 trial of fasedienol, an investigational neuroactive pherine nasal spray in u.s. registration-directed phase 3 development for.
VTGN Ratings Summary
VTGN Quant Ranking